8-K current report · filed Sep 16, 2026

Teva Pharmaceutical Industries Ltd (TEVA) 8-K Current Report: September 16, 2026

Item 1.01Item 2.03TEVA overview

Short answer

Teva Pharmaceutical Industries Ltd (TEVA) filed an 8-K current report with the SEC on September 16, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 2.03 (Creation of a Direct Financial Obligation). $4.7B senior notes issued across euro and dollar markets, extending Teva’s debt maturities through 2037.

Teva Pharmaceutical Industries Ltd 8-K event analysis

AI summary of each reported item and its exhibits

Item 1.01 · Entry into a Material Definitive Agreement

  • $4.7B senior notes issued across euro and dollar markets, extending Teva’s debt maturities through 2037
  • Coupon rates range from 4.250% to 5.750%, creating substantial ongoing interest expense
  • Proceeds primarily fund redemption of higher-coupon notes, including 8.125% notes due 2031 and 7.875% notes due 2029
  • Refinancing may reduce borrowing costs, while maintaining significant leverage and senior unsecured obligations guaranteed by Teva
  • Conditional redemptions include up to €1.15B of 4.375% notes due 2030 and $450M of 4.750% notes due 2027

Other items in this filing:

  • Item 2.03: Creation of a Direct Financial Obligation

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Teva Pharmaceutical Industries Ltd 8-K filings

Get the next TEVA 8-K as it lands

Follow TEVA for push alerts, or ask the research agent what this filing means.